Clinical trial
Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors
NCT00106353 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00106353 |
|---|---|
| Title | Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors |
| Official title | A Phase I/II Safety and Exploratory Pharmacogenomic/Pharmacodynamic Study of Intravenous Temsirolimus (CCI-779) in Pediatric Subjects With Relapsed/Refractory Solid Tumors |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma, Neoplasms |
| Intervention type | Drug |
| Interventions | Torisel |
| Enrollment | 71 |
| Start date | Mar 1, 2005 |
| Primary completion | Oct 1, 2009 |
| Completion | Jan 1, 2012 |
| First posted | Mar 23, 2005 |
| Last update posted | Feb 8, 2013 |
| Countries | Canada, France, Germany, Mexico, Poland, Russia, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: